Even though, in this type of tumor, the search of an adequate, specific TAA that directs the immune reaction towards the tumor cells and causes minimal damage to healthy cells is very complex, unlike what occurs in hematological neoplasms with CD19, and the solution of this problem will be in the numerous clinical trials with such different approaches [93]. The gene discussed is CD19; the disease is neoplasm.